Targeting new markets

How to reach us

M1 Kliniken AG
Grünauer Straße 5
12557 Berlin
Germany

T. +49 (0)30 347 47 44 14
E.

For medical consultation appointments contact: https://www.m1-beauty.de/termine/

Contact

Data protection*

Latest news

| Investor News

The Supervisory Board of M1 Kliniken AG has appointed Ms. Katharina Zimmnau to the Executive Board of M1 Kliniken AG with effect from 10. December 2025.

| Investor News

  • Group revenue: +6.7% to EUR 274.3 million (YTD Q3 2024: EUR 257.2 million)
  • EBITDA: +9% to EUR 28.2 million (YTD Q3 2024: EUR 25.9 million)
  • EBIT: +11% to EUR 24.5 million (YTD Q3 2024: EUR 22.1 million)
  • EBIT margin: 8.9% (YTD Q3 2024: 8.6%)
  • EBT: +10% to EUR 24.4 million (YTD Q3 2024: EUR 22.2 million)
  • Earnings per share: EUR 0.86 (YTD Q3 2024: EUR 0.77)

| Ad-hoc news

M1 Kliniken AG announces that its 85% subsidiary, HAEMATO AG, today signed an agreement for the sale of its wholly owned subsidiary HAEMATO Pharm GmbH to the PHOENIX group, one of Europe’s leading healthcare providers headquartered in Mannheim. The completion of the transaction remains subject to the customary antitrust approvals. The parties have agreed not to disclose the financial details of the transaction.

With this transaction, M1 Kliniken AG is consistently pursuing its strategic course to position itself as a globally leading, vertically integrated pure-play provider in the field of medical aesthetics.

| Investor News

  • Group revenue: +9.4% to EUR 183.5 million (H1 2024: EUR 167.7 million)
  • EBITDA: +21% to EUR 20.5 million (H1 2024: EUR 17.0 million)
  • EBIT: +24% to EUR 18.0 million (H1 2024: EUR 14.5 million)
  • EBIT margin: 9.8% (H1 2024: 8.6%)
  • EBT: +12% to EUR 16.9 million (H1 2024: EUR 15.0 million)
  • Earnings per share: EUR 0.63 (H1 2024: EUR 0.53)